SNS-103 / Sensei Biotherap - LARVOL DELTA

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference (GlobeNewswire) - "Sensei Biotherapeutics, Inc...today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD."

Preclinical • Oncology • Solid Tumor

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) - "Recent updates include: Sensei has completed lead optimization for its programs SNS-102 (targeting VSIG4) and SNS-103 (targeting CD-39) and is currently characterizing potential lead antibodies for each program. Sensei remains on track to select product candidates for both SNS-102 and SNS-103 in 2023. Sensei’s early discovery bispecific antibody program has generated an initial set of conditionally active bispecific antibodies that are currently being characterized. Upon successful candidate selection, Sensei expects to advance one product candidate to IND-enabling studies."

Pipeline update • Oncology • Solid Tumor

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) - "Sensei Biotherapeutics...presented new preclinical data on its SNS-103 program aimed at developing a conditionally active, monoclonal antibody program targeting ENTPDase1 (also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023....CD39 is commonly upregulated in the tumor microenvironment, which is characterized by high levels of extracellular ATP (eATP) and low pH. Upregulation and activation of CD39 results in significant reductions of eATP and a rise in immunosuppressive adenosine."

Preclinical • Oncology • Solid Tumor

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights (GlobeNewswire) - "Upcoming Milestones: Sensei will present preclinical data on its SNS-103 program at the American Association for Cancer Research (AACR) Annual Meeting in a poster session on April 18, 2023. Sensei remains on track to select product candidates for both SNS-102 and SNS-103 in 2023. Upon successful candidate selection, Sensei expects to advance at least one product candidate to IND-enabling studies....R&D expenses were $30.4 million for the year ended December 31, 2022, compared to $21.7 million for the year ended December 31, 2021. The increase in R&D expenses was primarily attributable to increased manufacturing and early development activities for the Company’s lead program SNS-101, partially offset by a decrease in clinical trial expenses."

Commercial • Preclinical • Oncology • Solid Tumor

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 (GlobeNewswire) - "Sensei Biotherapeutics...will present new preclinical data on SNS-103, a conditionally active, monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, FL."

Preclinical • Oncology

Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) - "SNS-101: The Company intends to present new data from a multi-dose pharmacokinetic (PK) and toxicology model in non-human primates in the first half of 2023. Sensei remains on track to select a product candidate for SNS-102 in 2023; SNS-103: The Company began screening the first set of parental antibodies in September 2022 and remains on track to select a product candidate in 2023."

Clinical • Preclinical • Oncology • Solid Tumor

Sensei Biotherapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) - "Highlights and Milestones: SNS-101: The Company plans to present new data from a single dose pharmacokinetic (PK) and toxicology model in non-human primates in the third quarter of 2022. Sensei will present new preclinical cytokine release data comparing SNS-101 to a non-pH-selective anti-VISTA antibody at the Sixth CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival, being held September 28 - October 1, 2022 in New York City; SNS-103: Sensei remains on track to select a product candidate in 2023 for SNS-103, a monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39), the upstream, rate-limiting enzyme that leads to the breakdown of extracellular ATP."

Clinical • Preclinical • Oncology • Solid Tumor